Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
about
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.Surrogate end points in early prostate cancer clinical states: ready for implementation?Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.Pre-treatment F-choline PET/CT is prognostic for biochemical recurrence, development of bone metastasis, and cancer specific mortality following radical local therapy of high-risk prostate cancerSurrogate endpoints in early prostate cancer research
P2860
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Metastasis-Free Survival Is a ...... in Localized Prostate Cancer.
@en
type
label
Metastasis-Free Survival Is a ...... in Localized Prostate Cancer.
@en
prefLabel
Metastasis-Free Survival Is a ...... in Localized Prostate Cancer.
@en
P2093
P2860
P356
P1476
Metastasis-Free Survival Is a ...... in Localized Prostate Cancer.
@en
P2093
Bertrand Tombal
Christopher J Sweeney
Howard M Sandler
Howard Soule
ICECaP Working Group
James J Dignam
Laurence Collette
Marc Buyse
Matthew R Sydes
Meredith M Regan
P2860
P304
JCO2017739987
P356
10.1200/JCO.2017.73.9987
P407
P577
2017-08-10T00:00:00Z